Aren't there any 2nd generation nukes in development for HIV that could supercede tenofovir disoproxil and emtricitabine in a more potent combo formulation (and then add in a better PI than Sustiva)?
Wouldn't this be a pretty good way to break Gilead's stranglehold on the market?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.